However, despite the facts that AAA is a chronic inflammatory disease, and innate or adaptive immune responses have emerged as promising targets to limit human AAA [4], the potential of PDE4 enzymes as therapeutic targets for this disorder has not been previously addressed. The gene discussed is PDE4A; the disease is triple-A syndrome.